Rigel Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Rigel Pharmaceuticals Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Rigel Pharmaceuticals Inc Strategy Report

  • Understand Rigel Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Rigel Pharmaceuticals Inc: Overview

Select Item

Rigel Pharmaceuticals Inc (Rigel) is a biotechnology company that discovers and develops innovative small-molecule drugs for patients with immune disorders, hematological disorders, cancer, and rare diseases. Its research activities focus on signaling pathways that are critical to disease mechanisms. The company’s lead product, the US FDA approved Tavalisse (fostamatinib disodium hexahydrate), is an oral spleen tyrosine kinase inhibitor to treat adult patients with chronic immune thrombocytopenia; and Rezlidhia (olutasidenib) for the treatment of adult patients with R/R AML with a susceptible IDH1 mutation. Rigel is also evaluating Fostamatinib for autoimmune hemolytic anemia and IgA nephropathy in Phase II trials. The company has partnered clinical programs with Aclaris, BerGenBio, Daiichi, AstraZeneca, Kissei, Grifols, Merck and Novartis. Rigel is headquartered in South San Francisco, California, the US.

 Gain a 360-degree view of Rigel Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Rigel Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 611 Gateway Boulevard, Suite 900, South San Francisco, California, 94080
Website www.rigel.com
Telephone 1 650 6241100
No of Employees 147
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange RIGL (NASD)
Revenue (2022) $116.9M -2.8% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 57.2% (2022 vs 2021)
Market Cap* $210.5M
Net Profit Margin (2022) XYZ 55.9% (2022 vs 2021)
* As of and is in US$
View Rigel Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Rigel Pharmaceuticals Inc premium industry data and analytics

60+

Clinical Trials

Determine Rigel Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Rigel Pharmaceuticals Inc’s relevant decision makers and contact details.

40+

Catalyst Calendar

Proactively evaluate Rigel Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

20+

Pipeline Drugs

Identify which of Rigel Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

2

Sales & Consensus Forecasts

Understand the current and future drug revenue for Rigel Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Rigel Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Rigel Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
-
Tavalisse (fostamatinib disodium hexahydrate):
Chronic Immune Thrombocytopenic Purpura (ITP)
XYZ
XYZ
XYZ
Understand Rigel Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Rigel Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In February, the company entered into an agreement to acquire the US rights to GAVRETO from Blueprint Medicines Corporation.
2023 Contracts/Agreements In December, the company entered into an agreement with The University of Texas MD Anderson Cancer Center to further investigate REZLIDHIA in acute myeloid leukemia (AML) and other hematologic malignancies.
2023 Regulatory Approval In January, the company’s REZLIDHIA (olutasidenib) has been added to National Comprehensive Cancer Network for the treatment of acute myeloid leukemia (AML).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Rigel Pharmaceuticals Inc AbbVie Inc Novartis AG Amgen Inc Gilead Sciences Inc
Headquarters United States of America United States of America Switzerland United States of America United States of America
City South San Francisco North Chicago Basel Thousand Oaks Foster City
State/Province California Illinois - California California
No. of Employees 147 50,000 76,057 26,700 18,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Gary A. Lyons Chairman Executive Board 2014 71
Raul R. Rodriguez President; Chief Executive Officer Executive Board 2014 62
Dean L. Schorno Chief Financial Officer; Executive Vice President Senior Management 2018 60
Wolfgang Dummer, MD, PhD Executive Vice President; Chief Medical Officer Senior Management 2019 57
David A. Santos Executive Vice President; Chief Commercial Officer Senior Management 2020 60
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Rigel Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Rigel Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward